Market closed
Palvella Therapeutics Inc/$PVLA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Palvella Therapeutics Inc
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
Ticker
$PVLA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
14
Website
PVLA Metrics
BasicAdvanced
$281M
-
-$7.83
-
-
Price and volume
Market cap
$281M
52-week high
$29.27
52-week low
$18.23
Average daily volume
96K
Financial strength
Current ratio
7.33
Quick ratio
7.139
Long term debt to equity
19.075
Total debt to equity
19.075
Interest coverage (TTM)
-3.26%
Management effectiveness
Return on assets (TTM)
-18.39%
Return on equity (TTM)
-59.37%
Valuation
Price to book
4.48
Price to tangible book (TTM)
4.48
Price to free cash flow (TTM)
-5.23
Growth
Earnings per share change (TTM)
-460.93%
PVLA News
AllArticlesVideos
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
GlobeNewsWire·2 days ago
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
GlobeNewsWire·3 days ago
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Palvella Therapeutics Inc stock?
Palvella Therapeutics Inc (PVLA) has a market cap of $281M as of April 25, 2025.
What is the P/E ratio for Palvella Therapeutics Inc stock?
The price to earnings (P/E) ratio for Palvella Therapeutics Inc (PVLA) stock is 0 as of April 25, 2025.
Does Palvella Therapeutics Inc stock pay dividends?
No, Palvella Therapeutics Inc (PVLA) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next Palvella Therapeutics Inc dividend payment date?
Palvella Therapeutics Inc (PVLA) stock does not pay dividends to its shareholders.
What is the beta indicator for Palvella Therapeutics Inc?
Palvella Therapeutics Inc (PVLA) does not currently have a Beta indicator.